

Conference Programme

Sunday 1 February

- 17:30 - 17:45** **Opening Remarks**
- 17:45 - 19:25** **Session 1 (Chair: Andrew Payne)**
- 17:45** **Paul Leeson**
Drug-like properties and decision-making in medicinal chemistry
- 18:35** **Karen Lackey**
Kinome Drug Discovery: Tykerb and Research Tools
- 19:25** **Group dinner reception**
-

Monday 2 February

- 09:00 - 12:50** **Session 2 (Chair: Paul Leeson)**
- 09:00** **Hashim Zuberi**
Carboxylic Derivatives of Ofloxacin and Ciprofloxacin; Synthesis, Characterization and Biological Activities
- 09:30** **Chris Dealwis**
structure-based drug and antibody
- 10:00 - 10:30** **Informal discussion and refreshments**
- 11:00** **Andrew Payne**
A Superior Antipsychotic: Rational Design or Irrational Dream?
- 11:50** **Volker Stadler**
Iterative high-throughput screening with high density peptidomimetic arrays
- 12:20** **Jordan Zjawiony**
Natural product-based ligands for kappa-opioid receptor
- 12:50 - 13:50** **Group lunch**

- 16:00 - 17:45** **Session 3 (Chair: Karen Lackey)**
- 16:00** **Andrew Hopkins**
What are the Challenges of Polypharmacology?
- 16:50** **Salvatore Guccione**
Targeting the Neuronal Cell Cycle: "Field Screen"
- 17:20** **Snehlata Chaudhary**
Effect of Hydrophobic Residues at the P1? Position of Tripeptidomimics on their Angiotensin Converting Enzyme Inhibition Potency
- 17:50 - 19:30** **Poster Session**
- 19:30** **Dine-around (choice of hotel restaurant)**
-

Tuesday 3 February

- 09:00 - 12:20** **Session 4 (Chair: Andrew Hopkins)**
- 09:00** **Arthur Gomtsyan**
From Chili Pepper to synthetic analgesics: Discovery of TRPV1 antagonist ABT-102 for treatment of pain
- 09:30** **Wolfgang Froestl**
Optimized positive allosteric modulators
- 10:00 - 10:30** **Informal discussion and refreshments**
- 10:30** **Bruce Rogers**
Activators of the $\alpha 7$ Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia and AD
- 11:20** **Yousef Al-Abed**
MIF is a novel target for drug discovery in autoimmune and inflammatory diseases
- 11:50** **Gebhard Thoma**
chemokine receptor antagonists in transplantation
- 12:20 - 13:30** **Group lunch**
- 16:30 - 19:30** **Session 5 (Chair: Bruce Rogers)**
- 16:30** **Amit Kalgutkar**
Structural Alerts, Reactive Metabolites and Protein Covalent Binding: How Reliable are these Attributes as Predictors of Drug Toxicity?
- 17:20** **Tom Solmajer**
Discovery of DNA gyrase B inhibitors

17:50 - 18:20 Informal discussion and refreshments

18:20 Andrew Thomas
TBC

19:10 Dramane Laine
Discovery of new long acting muscarinic antagonists (LAMA) for the Treatment of COPD

19:40 Group dinner

Wednesday 4 February

08:30 - 10:05 Session 6 (Chair: Andrew Payne)

08:30 Richard Hargreaves
TBC

09:20 Gjermund Henriksen
New route to 11C-GR103545 enables Positron Emission Tomography studies of kappa-opioid receptor function in humans

09:50 - 10:20 Informal discussion and refreshments

10:20 Bertrand Le Bourdonnec
Discovery of ADL5859, a Potent and Orally Bioavailable Delta Opioid Receptor Agonist for the Treatment of Pain

10:50 Jeffrey Albert
Challenges and successes in fragment-based lead generation: Discovery of high affinity beta-secretase inhibitors

11:20 Virginie Fruh
The fragment-based approach to drug discovery successfully applied to a membrane protein. Target Immobilized NMR screening and biochemical characterization for hit discovery

11:50 Closing Comments

12:00 Group lunch and departure
